Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stabilized plasmid-lipid particles for systemic gene therapy.

P Tam1, M Monck, D Lee

  • 1Inex Pharmaceuticals Corporation, Burnaby, BC, Canada.

Gene Therapy
|December 8, 2000
PubMed
Summary

Stabilized plasmid-lipid particles (SPLP) show promise as systemic gene therapy vectors. These non-toxic SPLP efficiently deliver plasmid DNA to tumors following intravenous injection, enabling reporter gene expression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genes dependent on zebrafish cyclops function identified by AFLP differential gene expression screen.

Genesis (New York, N.Y. : 2000)·2000
Same author

Appropriateness of the decision to transfer nursing facility residents to the hospital.

Journal of the American Geriatrics Society·2000
Same author

Dopamine induces a biphasic modulation of hypothalamic ANF neurons: a ligand concentration-dependent effect involving D5 and D2 receptor interaction.

Molecular psychiatry·2000
Same author

Rate of change of cerebral blood flow velocity with hyperventilation during anesthesia in humans.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2000
Same author

Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.

Breast cancer research and treatment·2000
Same author

Unaltered phenotype, tissue distribution and function of Valpha14(+) NKT cells in germ-free mice.

European journal of immunology·2000

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Nanomedicine

Background:

  • Systemic gene therapy requires efficient and safe delivery vectors.
  • Current methods like naked DNA or cationic liposomes have limitations in tumor targeting and toxicity.
  • Stabilized plasmid-lipid particles (SPLP) offer a potential alternative for gene delivery.

Purpose of the Study:

  • To investigate the structure and properties of SPLP as systemic gene therapy vectors.
  • To evaluate the efficacy and safety of SPLP in a murine tumor model.

Main Methods:

  • Cryo-electron microscopy was used to visualize SPLP structure.
  • Intravenous injection of SPLP, naked DNA, and DNA-liposome complexes in a murine tumor model.
  • Assessment of particle circulation half-life, tumor accumulation, reporter gene expression, and serum enzyme levels for toxicity.

Related Experiment Videos

Main Results:

  • SPLP are homogeneous particles (72 ± 5 nm) with a lipid bilayer and plasmid DNA core.
  • SPLP demonstrated long circulation half-lives (>6 h) and significant tumor accumulation (up to 3%).
  • SPLP enabled reporter gene expression in distal tumors, unlike naked DNA or liposome complexes, and exhibited low toxicity at high doses.

Conclusions:

  • SPLP possess favorable characteristics for systemic gene therapy.
  • SPLP demonstrate efficient tumor targeting, gene delivery, and a favorable safety profile.
  • SPLP represent a promising non-toxic vector for systemic gene therapy applications.